Search 

Pfizer Venture Investments (PVI) is the corporate venture capital arm of Pfizer and was founded in 2004. PVI has an annual investments budget of $50 million and invests up to $10M per investing round. The firm focuses mainly on U.S. startups but has global reach. PVI attempts to allocate 80% of its funding to U.S. based companies and utilizes the remaining 20% for international ventures. PVI provides equity funding for private companies in need of seed, growth, or venture financing. Remaining opportunistic, PVI focuses entirely on high growth prospects in all sectors and all phases of development. The ideal candidate has a potential for high growth and returns. Additionally, PVI will seek to in-license products and buyout companies if the opportunity arises.

Pharmatek is a contract development & manufacturing company providing dosage form development & cGMP manufacturing of oral, injectable & topical products. Founded in 1999, our services focus on the rapid advancement of small molecule & peptide drug candidates from the bench to the clinic & include:

·         Formulation & Analytical Development

·         cGMP Manufacturing

·         Clinical Packaging, Labeling & Worldwide Distribution

Our experience includes first-in-man strategies, solutions for poorly soluble compounds, controlled release formulations & separate facilities for the handling of cytotoxic & potent compounds.  Pharmatek’s drug delivery technologies include:

·         Solid Dispersions

·         Particle Size Reduction

·         Lipid Delivery

·         Complexation

·         Lyophilization

·         Suspensions & Emulsions

Pharmatek’s 68,000 sq. ft. facility includes 9 class 100,000 cGMP manufacturing suites, formulation & analytical laboratories, & ICH stability storage.  Pharmatek has over 150 clients globally, ranging from virtual to large pharmaceutical companies. Having manufactured product for clinical trials in the North America, Europe & Asia; Pharmatek has successfully completed several large pharma quality, EH&S & QP audits.

PlantForm Corporation is a Canadian company formed in 2008 to commercialize a low-cost, plant-based manufacturing platform for monoclonal antibodies, protein drugs and vaccines for cancer and other critical illnesses.

The company’s technology platform provides several advantages over mammalian cell culture and other fermentation systems used to produce most biologic drugs on the market today: it’s fast, efficient, highly versatile (for new product development) and easily scalable. Best of all, it’s capable of reducing manufacturing costs for life-saving drugs by up to 90 per cent.

PlantForm licenses its technology from the University of Guelph, where it was developed by Dr. J. Christopher Hall, a PlantForm founder and the company’s Chief Scientific Officer. Dr. Hall held the Canada Research Chair in Recombinant Antibody Technology from 2002 to 2014 and is a leading authority in the field. All relevant intellectual property is protected by patent filings.

PlantForm’s pipeline features both innovator and biosimilar products, including:

• biosimilar trastuzumab, a plant-produced version of the $6-billion breast cancer drug Herceptin® (animal studies successfully completed, human clinical trials scheduled for 2014, market entry anticipated 2017)

• biosimilar versions of two additional oncology drugs with combined annual global sales of $11.4 billion (2010)

• innovator antibodies for HIV/AIDS, funded by the Government of Canada and the Bill & Melinda Gates Foundation

• recombinant butyrylcholinesterase (rBuChE), an enzyme used as preventative medicine for people vulnerable to attack by nerve agents, organophosphates or other stimulants ($1.8-million contract with the U.S. Defense Advanced Research Projects Agency and $800,00 contract with Defence Canada)

Plug and Play Ventures (a successor fund to Amidzad Partners) is a private/family investment vehicle based in Silicon Valley, CA. The fund is a structured organization for making angel investments in pre-seed or seed rounds. Investments are in the form of equity; in the next 6 months Plug and Play Ventures expects to make about 5-10 seed investments of $50,000-100,000 and an additional 40 pre-seed investments of $25,000, and is hoping to increase their allocations in the healthcare sector. Plug and Play also provides a three-month accelerator program. The firm will consider investing in companies worldwide.

Plug and Play Ventures is interested in investing in medical technology, and invests in subsectors in which the firm can apply expertise; typically this means products that have a significant software component. Healthcare IT, biosensors, wearables and health monitoring devices are of interest. While the firm is open to investing in any indication, Plug and Play is particularly interested in diabetes & blood glucose monitoring, personal fitness, and mental/behavioral disorders. In the healthcare IT sector, Plug and Play Ventures is interested in both consumer applications and enterprise software, but is not interested in diagnostic software such as genomic, proteomic, or molecular diagnostic algorithms; however, optimization and data analysis software for hospitals and diagnostic laboratories is of interest.

Plug and Play Ventures (a successor fund to Amidzad Partners) is a private/family investment vehicle based in Silicon Valley, CA. The fund is a structured organization for making angel investments in pre-seed or seed rounds. Investments are in the form of equity; in the next 6 months Plug and Play Ventures expects to make about 5-10 seed investments of $50,000-100,000 and an additional 40 pre-seed investments of $25,000, and is hoping to increase their allocations in the healthcare sector. Plug and Play also provides a three-month accelerator program. The firm will consider investing in companies worldwide.  

Plug and Play Ventures is interested in investing in medical technology, and invests in subsectors in which the firm can apply expertise; typically this means products that have a significant software component. Healthcare IT, biosensors, wearables and health monitoring devices are of interest. While the firm is open to investing in any indication, Plug and Play is particularly interested in diabetes & blood glucose monitoring, personal fitness, and mental/behavioral disorders. In the healthcare IT sector, Plug and Play Ventures is interested in both consumer applications and enterprise software, but is not interested in diagnostic software such as genomic, proteomic, or molecular diagnostic algorithms; however, optimization and data analysis software for hospitals and diagnostic laboratories is of interest.

Prolog Ventures is a venture capital firm based out of St. Louis Missouri that was founded in 2001. The firm is currently making investments out of its vintage 2013 4th fund of approximately $100 million. The firm is looking to make equity investments in companies ranging from $500,000 to $3 million. The firm will invest in companies across the United States and plans to make approximately 3-4 investments over the next 6-9 months.

PxRadia is applying its HD-mAb technology platform to provide increased therapeutic potency to biosimiliar monoclonal antibodies. These antibodies are directed to validated targets such as Her-2, CD-20 and PD-1/PD-L.  We and our partners will share new IP and rights and differentiation from current products in the marketplace.

Quintessence Biosciences, Inc. is a private, clinical stage biopharmaceutical company developing novel anti-cancer compounds based on our patented EVade™ Ribonuclease technology. The lead candidate, called QBI-139, completed a first in human dose escalation Phase I clinical trial in patients with solid tumors. Quintessence is looking for funding for a proof of concept clinical trial (Phase Ib/IIa) with a defined patient population.